The uncertainty map: how to find the one risk holding your asset's value hostage
Most biotech development plans answer the wrong question. The uncertainty map identifies which single risk, retired first, creates the most value per euro spent.
Most biotech development plans are written as timelines. A list of activities, arranged in sequence, with estimated costs attached to each. Phase one begins in Q1. The IND is filed in Q3. The first patient is enrolled by the end of the year.
These plans are not wrong, exactly. But they answer the wrong question. A timeline tells you what will happen and when. It does not tell you which activity, completed first, creates the most value per euro spent. And in a capital-constrained environment, that is the only question that matters.
The difference between a development plan built around activities and one built around uncertainty reduction is the difference between managing a project and building an asset. The former produces progress reports. The latter produces deals.
Why risk in biotech is multiplicative, not additive
To understand why the uncertainty map matters, it helps to understand how value is calculated in early-stage biotech.
Investors and pharma business development teams use a tool called risk-adjusted net present value, or rNPV. It works like this: estimate the future revenues the asset could generate if it reaches market, then multiply by the cumulative probability of getting there. That cumulative probability is the product of several independent risk components: clinical, regulatory, manufacturing, commercial, and sometimes IP.
When risks are multiplicative, a small improvement in the weakest component produces a disproportionately large improvement in total expected value.
The mathematics here are important. When risks are multiplicative, the relationship between individual components and total value is not linear. A small improvement in the weakest component produces a disproportionately large improvement in total expected value.
Illustrative example: the mathematics of multiplicative risk
Consider a typical post-Phase I asset. These numbers are illustrative. In practice, every probability estimate must be calibrated to the specific asset, indication, and development stage, using comparable transactions, published success rates, and scientific judgment. The point is not the numbers themselves. It is the mathematics they reveal.
Now suppose a manufacturing doubt reduces the manufacturing probability to 50%. Cumulative probability falls to 14%. Expected value drops to €140M. The market did not change. The science did not change. One uncertainty moved, and the asset lost €110M of expected value.
This is not an abstract calculation. It is the calculation every serious investor and every pharma business development team is running, whether they make it explicit or not. The founder who understands this arithmetic has a fundamental advantage over the one who does not.
What a gating uncertainty is
A gating uncertainty is the component that dominates all others. It is the locked gate that prevents the rest of the project from expressing its economic potential.
The concept sounds simple. In practice, identifying the gating uncertainty correctly is harder than it appears, for two reasons.
Bias one: scientific fascination
The gating uncertainty is not always the most scientifically interesting problem. Founders naturally focus their attention and their capital on the questions they find most compelling. But the question that is scientifically interesting and the question that is economically gating are often not the same question.
Bias two: inherited plans
The gating uncertainty is often not the one the team is working on. Development plans are frequently inherited from previous iterations of the project, shaped by available expertise, or driven by funder requirements. The activity that happens to be next on the timeline is not necessarily the activity that creates the most value per euro.
The uncertainty map asks a simple question: which single uncertainty, retired with the available capital, moves the cumulative probability of a deal by the most?
How to build the uncertainty map
The process has four steps.
Before mapping uncertainties, you need to know where you are going. Which company would acquire this asset? What does their investment committee require? A pharma company evaluating a licensing deal uses the same rNPV framework. They have threshold conditions: clinical proof of concept, regulatory clarity, manufacturing stability, IP protection, pipeline fit. Map your uncertainties against those conditions, not against your own internal development milestones.
Not every risk, every critical uncertainty. The distinction matters. A risk is anything that could go wrong. A critical uncertainty is a condition that, unresolved, would prevent the deal from proceeding. Work through each dimension: clinical efficacy, safety profile, regulatory pathway, manufacturing scalability, IP strength in key markets, competitive landscape, reimbursement logic. Be specific. "Clinical risk" is not an uncertainty. "The absence of proof-of-concept data in the primary indication at the therapeutic dose" is an uncertainty.
This does not require precision. It requires honesty. Use comparable transactions, published success rates by indication and modality, and your own scientific judgment. The goal is not an accurate number. The goal is a ranked order that identifies where the leverage is.
Take your current cumulative probability. Now resolve each uncertainty in turn and recalculate. Which single resolution moves the total by the most? That is your gating uncertainty. That is where the next euro should go.
The sequence matters as much as the activity
One of the most common and most expensive mistakes in biotech development is pursuing the right activities in the wrong order.
Wrong sequence
There is no rational case for spending a million euros to improve manufacturing efficiency when the clinical proof of concept remains unresolved. If the clinical data does not come in, the manufacturing improvement is worthless.
Right sequence
Good clinical data with imperfect manufacturing can still attract capital, because manufacturing problems are generally solvable. Clinical failures are not.
The sequence of uncertainty resolution is a strategic decision, not a logistical one. It determines the shape of your fundraising conversations, the credibility of your milestone map, and ultimately the valuation you can defend at each stage.
Founders who sequence correctly tend to raise at higher valuations, because each round begins from a position of maximum de-risking relative to the capital deployed. Founders who sequence incorrectly tend to raise at flat or down valuations, because the capital was spent on activities that did not move the probability needle.
The question that changes how you allocate capital
Which uncertainty, retired with this capital, moves the cumulative probability of a deal by the most?
This question changes the conversation in the room. It shifts the frame from "what are we doing next?" to "what must we prove, and why does proving it matter to the person who will eventually write the cheque?"
It also changes what gets cut. Most development budgets contain activities that are scientifically interesting, operationally convenient, or politically important within the institution. The uncertainty map creates an objective basis for deprioritising them. If an activity does not resolve a critical uncertainty, it belongs in a publication, not a development plan funded by investor capital.
This is uncomfortable for research teams. It should be. The discomfort is productive. It is the difference between managing a scientific programme and building a company.
What the map reveals
The most useful thing about building an uncertainty map is not the map itself. It is what the process reveals about the assumptions the team has been making.
In almost every case, the exercise surfaces at least one critical uncertainty that the team had been treating as a background condition rather than an active risk. Something everyone knew was unresolved but nobody had quantified. Something that, once made explicit, turns out to dominate the cumulative probability calculation.
That revelation is uncomfortable. It is also the most valuable thing a founder can learn before sitting down with an investor. Because the investor will find it. They always do. The only question is whether the founder finds it first, and has a credible plan to address it.
The uncertainty map is not a guarantee of funding. It is a guarantee of clarity. And in early-stage biotech, clarity is the rarest and most valuable asset of all.
Leonardo Biondi works with biotech founders and technology transfer offices to build the investment architecture that sits underneath the pitch deck. If you want to map the uncertainties in your own asset before your next investor conversation, book a 30-minute call at biondi.pro/contact.